加速纤维分解:倾向于出血?
Dino Mehic1, Ingrid Pabinger1, Johanna Gebhart1
1Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Hamostaseologie
|April 27, 2025
概括
过敏纤维素溶解是一种出血障碍,在轻度至中度出血障碍和原因不明的出血障碍中经常被忽视. 本综述探讨了其评估和用胺酸进行的治疗.
科学领域:
- 血液学 血液学 血液学
- 血液静止和血栓形成
- 临床病理学 临床病理学
背景情况:
- 过纤维素分解是轻度至中度出血障碍 (MBDs) 和原因不明的出血障碍 (BDUC) 的不足研究的原因.
- 遗传性高纤维素分解性疾病可以表现为轻度或重度出血症状.
- 这些疾病包括α2-抗等离子素 (α2-AP) 和等离子素激活剂抑制剂1型 (PAI-1) 的缺乏,北克血小板疾病和组织等离子素激活剂 (tPA) 过量.
研究的目的:
- 审查目前关于MBD和BDUC患者的高纤维素分解的数据.
- 总结评估高纤维素分解的方法.
- 讨论这些患者群体中高纤维素溶解的临床影响和治疗.
主要方法:
- 对MBD和BDUC中的超纤维素分解现有文献的综述.
- 分析各种评估方法:纤维解质因子测量,全球静血测试 (粘弹性测试,基于度的血凝块溶解) 和化等离子体生成 (PG).
- 在BDUC患者中对tPA-ROTEM和PG测定结果的评估.
主要成果:
- 证据将高纤维素分析特征与出血严重程度联系起来不一致.
- 在BDUC中报告了增加的tPA活性和血栓可激活纤维解酶抑制剂和α2-AP的矛盾增加.
- 在tPA-ROTEM测定中,高达20%的BDUC患者发现过敏纤维素分解;PG分析显示了区分BDUC患者的预测能力.
结论:
- 全球纤维解质试验可能有助于确定高纤维解质是导致一些MBD/BDUC患者出血的原因.
- 测量特定纤维素分析因子的临床实用性需要进一步研究.
- 特兰胺酸是遗传性过纤维素分解以及面临血静挑战的MBD/BDUC患者的推治疗方法.
相关概念视频
Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
Extrinsic and Intrinsic Pathways of Hemostasis
3.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
3.6K
Introduction to Hemostasis
3.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
3.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
991
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
991
Formation of the Platelet Plug
2.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
2.7K


